TAKARA BIO INC, AnGes MG, Inc
World news –JP –Corona vaccine manufacturing system development Takara Bio invests 9.5 billion yen Possibility to expand mass production ｜ Medical / Corona ｜ Regional news ｜ Kyoto Shimbun
Related title :
– Establishing corona vaccine manufacturing system Takara Bio invests 9.5 billion yen Possibility to expand mass production
-<a href="/?s=Anges's contracted vaccine manufacturing Takara Bio is high, 21 years With the increase in the business forecast for the fiscal year ending March 31, 2009, Takara Bio, which is contracted to manufacture vaccines for Anges, is high, and with the increase in the business forecast for the fiscal year ending March 31, 2009,
– Takara Bio suddenly returned, and the 11th consecutive year of record high profits greatly increased the previous outlook
– Takara Bio’s net profit increased by 31% in the fiscal year ended March 31, 2009, vaccines were strong
– Takara Bio, highest profit = PCR demand, forecast revised upward-FY03 / 21 ja
SOURCE: https://www.w24news.com